AZD8205(AstraZeneca)은 Breast Cancer 표적 ADC로, Breast Cancer; Biliary Tract Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: and efficacy studies were conducted in human cancer cell line and patient-derived xenograft (PDX) models. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 3건의 관련 임상이 등록되어 있습니다. 차별점: novel topoisomerase I inhibitor payload, with durable DAR, currently being studied in the clinic for the potential treatment.
Breast Cancer
Breast Cancer; Biliary Tract Carcinoma
Recruiting
ADCs) are a promising drug modality substantially expanding in
PL
linker-payload (PL) conjugation sites on the antibody
novel topoisomerase I inhibitor payload, with durable DAR, currently being studied in the clinic for the potential treatment
and efficacy studies were conducted in human cancer cell line and patient-derived xenograft (PDX) models
topoisomerase I inhibitor ADC, AZD8205, puxitatug samrotecan, that underpin its structural stability in vivo using an intact protein
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
AZD8205(AstraZeneca)은 Breast Cancer 표적 ADC로, Breast Cancer; Biliary Tract Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: and efficacy studies were conducted in human cancer cell line and patient-derived xenograft (PDX) models. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 3건의 관련 임상이 등록되어 있습니다. 차별점: novel topoisomerase I inhibitor payload, with durable DAR, currently being studied in the clinic for the potential treatment.
Breast Cancer
Breast Cancer; Biliary Tract Carcinoma
Recruiting
ADCs) are a promising drug modality substantially expanding in
PL
linker-payload (PL) conjugation sites on the antibody
novel topoisomerase I inhibitor payload, with durable DAR, currently being studied in the clinic for the potential treatment
and efficacy studies were conducted in human cancer cell line and patient-derived xenograft (PDX) models
topoisomerase I inhibitor ADC, AZD8205, puxitatug samrotecan, that underpin its structural stability in vivo using an intact protein
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.